4.7 Review

Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 178, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2021.113909

Keywords

Breast cancer metastasis; Nanomedicine; Drug delivery system; Anti-metastasis therapy; Primary tumor; Pre-metastatic niches; Circulating tumor cells; Secondary tumor

Funding

  1. National Natural Science Foundation of China [81961138009]
  2. 111 Project [B18035]
  3. Key Research and Development Program of Science and Technology Department of Sichuan Province [2020YFS0570]

Ask authors/readers for more resources

Breast cancer is the most common tumor in women and its metastasis increases malignancy and mortality. Nanomedicines have shown great potential in treating cancer metastasis by specifically designed functions at different stages of the process, providing new solutions.
Breast cancer is the most common tumor in women, and the metastasis further increases the malignancy with extremely high mortality. However, there is almost no effective method in the clinic to completely inhibit breast cancer metastasis due to the dynamic multistep process with complex pathways and scattered occurring site. Nowadays, nanomedicines have been evidenced with great potential in treating cancer metastasis. In this review, we summarize the latest research advances of nanomedicines in anti-metastasis treatment. Strategies are categorized according to the metastasis dynamics, including primary tumor, circulating tumor cells, pre-metastatic niches and secondary tumor. In each different stage of metastasis process, nanomedicines are designed specifically with different functions. At the end of the review, we give our perspectives on current limitations and future directions in anti-metastasis therapy. We expect the review provides comprehensive understandings of anti-metastasis therapy for breast can-cer, and boosts the clinical translation in the future to improve women's health. (c) 2021 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available